Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research

Author: Wayne R. Danter

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Conversion of human somatic cells into induced pluripotent stem cells (iPSCs) is often an inefficient, time consuming and expensive process. Also, the tendency of iPSCs to revert to their original somatic cell type over time continues to be problematic. A computational model of iPSCs identifying genes/molecules necessary for iPSC generation and maintenance could represent a crucial step forward for improved stem cell research. The combination of substantial genetic relationship data, advanced computing hardware and powerful nonlinear modeling software could make the possibility of artificially-induced pluripotent stem cells (aiPSC) a reality. We have developed an unsupervised deep machine learning technology, called DeepNEU that is based on a fully-connected recurrent neural network architecture with one network processing layer for each input. DeepNEU was used to simulate aiPSC systems using a defined set of reprogramming transcription factors. Genes/proteins that were reported to be essential in human pluripotent stem cells (hPSC) were used for system modelling.

Results

The Mean Squared Error (MSE) function was used to assess system learning. System convergence was defined at MSE < 0.001. The markers of human iPSC pluripotency (N = 15) were all upregulated in the aiPSC final model. These upregulated/expressed genes in the aiPSC system were entirely consistent with results obtained for iPSCs.

Conclusion

This research introduces and validates the potential use of aiPSCs as computer models of human pluripotent stem cell systems. Disease-specific aiPSCs have the potential to improve disease modeling, prototyping of wet lab experiments, and prediction of genes relevant and necessary for aiPSC production and maintenance for both common and rare diseases in a cost-effective manner.
Literature
1.
Briggs R, King TJ. Transplantation of living nuclei from blastula cells into enucleated frogs’ eggs. Proc Natl Acad Sci. 1952;38:455–63.CrossRef
2.
Gurdon J, Laskey R. The transplantation of nuclei from single cultured cells into enucleate frogs’ eggs. Development. 1970;24:227–48.
3.
Wilmut I, Schnieke AE, McWhir J, amp Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810.CrossRef
4.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell. 2006;126:663–76.CrossRef
5.
Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007a;2:3081.CrossRef
6.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. cell. 2007b;131:861–72.CrossRef
7.
Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. Jama. 2006;296:1727–32.CrossRef
8.
Kobayashi Y, Fukami T, Nakajima A, Watanabe A, Nakajima M, Yokoi T. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2012;40:671–9.CrossRef
9.
Siller R, Greenhough S, Park I-H, J Sullivan G. Modelling human disease with pluripotent stem cells. Current gene therapy. 2013;13:99–110.CrossRef
10.
Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7:e1000245.CrossRef
11.
Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaug AJ, Crary SM, Choi J, Sebastiano V, Cherry A. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature. 2011;474:399.CrossRef
12.
Chamberlain SJ, Chen P-F, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, Lalande M. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader–Willi syndromes. Proc Natl Acad Sci. 2010;107:17668–73.CrossRef
13.
Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012;482:216.CrossRef
14.
Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010;120:3127–36.CrossRef
15.
Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471:230.CrossRef
16.
Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med. 2009;15:59–68.CrossRef
17.
Kinnear C, Chang WY, Khattak S, Hinek A, Thompson T, de Carvalho Rodrigues D, Kennedy K, Mahmut N, Pasceri P, Stanford WL. Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells. Stem Cells Transl Med. 2013;2:2–15.CrossRef
18.
Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci. 2009;106:12759–64.CrossRef
19.
Beers J, Linask KL, Chen JA, Siniscalchi LI, Lin Y, Zheng W, Rao M, Chen G. A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Sci Rep. 2015;5:11319.CrossRef
20.
Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee M, Ji H, Ehrlich L. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467:285.CrossRef
21.
Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013;13:149–59.CrossRef
22.
Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, Li W, Weng Z, Chen J, Ni S. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6:71–9.CrossRef
23.
Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O’malley R, Castanon R, Klugman S. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011;471:68.CrossRef
24.
Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3:568–74.CrossRef
25.
Chen Y, Yang Z, Zhao Z-A, Shen Z. Direct reprogramming of fibroblasts into cardiomyocytes. Stem Cell Res Ther. 2017;8:118.CrossRef
26.
Ehrhart F, Coort SL, Cirillo E, Smeets E, Evelo CT, Curfs LM. Rett syndrome–biological pathways leading from MECP2 to disorder phenotypes. Orphanet journal of rare diseases. 2016;11:158.CrossRef
27.
Yu K-R, Shin J-H, Kim J-J, Koog MG, Lee JY, Choi SW, Kim H-S, Seo Y, Lee S, Shin T-h. Rapid and efficient direct conversion of human adult somatic cells into neural stem cells by HMGA2/let-7b. Cell Rep. 2015;10:441–52.CrossRef
28.
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature genetics. 1999;23:185.CrossRef
29.
Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S. Characterization of human embryonic stem cell lines by the international stem cell initiative. Nat Biotechnol. 2007;25:803.CrossRef
30.
Ojala M, Rajala K, Pekkanen-Mattila M, Miettinen M, Huhtala H, Aalto-Setälä K. Culture conditions affect cardiac differentiation potential of human pluripotent stem cells. PLoS One. 2012;7:e48659.CrossRef
31.
Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295.CrossRef
32.
Pe'er D. Bayesian network analysis of signaling networks: a primer. In: Sci STKE 2005; 2005. p. pl4.
33.
Bornholdt S. Boolean network models of cellular regulation: prospects and limitations. J R Soc Interface. 2008;5:S85–94.CrossRef
34.
Nakaoka S. Multiscale mathematical modeling and simulation of cellular dynamical process. In: Epidermal Cells (Springer); 2014. p. 269–83.
35.
Frades I, Matthiesen R. Overview on techniques in cluster analysis. In: Bioinformatics Methods In Clinical Research; 2010. p. 81–107.CrossRef
36.
Grys BT, Lo DS, Sahin N, Kraus OZ, Morris Q, Boone C, Andrews BJ. Machine learning and computer vision approaches for phenotypic profiling. J Cell Biol. 2017;216:65–71.CrossRef
37.
38.
Bian Q, Cahan P. Computational tools for stem cell biology. Trends Biotechnol. 2016;34:993–1009.CrossRef
39.
Lipton ZC, Berkowitz J, Elkan C. A critical review of recurrent neural networks for sequence learning. arXiv preprint arXiv:150600019; 2015.
40.
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.CrossRef
41.
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499.CrossRef
42.
Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315–26.CrossRef
43.
Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG. Core transcriptional regulatory circuitry in human embryonic stem cells. cell. 2005;122:947–56.CrossRef
44.
Hamazaki T, El Rouby N, Fredette NC, Santostefano KE, Terada N. Concise review: induced pluripotent stem cell research in the era of precision medicine. Stem Cells. 2017;35:545–50.CrossRef
45.
Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001;19:193–204.CrossRef
46.
Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10:55.CrossRef
47.
Tachibana M, Amato P, Sparman M, Gutierrez NM, Tippner-Hedges R, Ma H, Kang E, Fulati A, Lee H-S, Sritanaudomchai H. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell. 2013;153:1228–38.CrossRef
48.
Vallier L, Alexander M, Pedersen RA. Activin/nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci. 2005;118:4495–509.CrossRef
49.
Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A, Orlov YL, Sung W-K, Shahab A, Kuznetsov VA. Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell. 2007;1:286–98.CrossRef
50.
Smarandache F. Neutrosophic logic-a generalization of the intuitionistic fuzzy logic. Multispace & Multistructure Neutrosophic Transdisciplinarity (100 collected papers of Science). 2010;4:396.
51.
Groumpos VP, Biniari K, Groumpos PP. A new mathematical modelling approach for viticulture and winemaking using fuzzy cognitive maps. Paper presented at: ELEKTRO, 2016 (IEEE); 2016.
52.
Wang H, Raj B, Xing EP. On the origin of deep learning. arXiv preprint arXiv:170207800; 2017.
53.
Kandasamy WV, Smarandache F. Fuzzy cognitive maps and neutrosophic cognitive maps (infinite study); 2003.
54.
William MA, Devadoss AV, Sheeba JJ. A study on Neutrosophic cognitive maps (NCMs) by analyzing the risk factors of breast Cancer. International Journal of Scientific & Engineering Research. 2013;4:1–4.
55.
Elliott DL. A better activation function for artificial neural networks; 1993.
Metadata
Title
DeepNEU: cellular reprogramming comes of age – a machine learning platform with application to rare diseases research
Author
Wayne R. Danter
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0983-3

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue

Research

A cost of illness study evaluating the burden of Wolfram syndrome in the United Kingdom

Research

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy

Research

Health service security of patients with 8 certain rare diseases: evidence from China’s national system for health service utilization of patients with healthcare insurance

Research

Retinal hyperreflective foci in Fabry disease

Research

Overall intact cognitive function in male X-linked adrenoleukodystrophy adults with normal MRI

Research

Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients